Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed Mar 1, 2022 · 10-K · 60 days after period end · 0000950170-22-002517
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $178.73M | $122.64M | $100.11M | $84.42M |
| Net Income | -$121.98M | -$189.32M | -$235.70M | -$140.90M |
| EPS Diluted | — | -$2.40 | -$3.16 | -$2.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Mar 1, 2022 · 60 d after period end
